News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pro-Pharmaceuticals, Inc. (PRW) Selects SAFC to Ramp-up the Manufacture of DAVANAT(R) for Anticipated Use in Clinical Trials & Sales in Colombia



5/3/2011 11:24:57 AM

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leader in Galectin Therapeutics, today announced it signed a multi-year agreement with SAFC®, the custom manufacturing business unit of Sigma-AldrichTM (Nasdaq: SIAL) to ramp-up the manufacture of the bulk drug substance or active pharmaceutical ingredient (API) for its lead product candidate, GM-CT-01 (DAVANAT®) for anticipated use in clinical trials and sales in Colombia, South America.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES